Target intelligence / Profile preview

Kelch-like ECH-associated protein 1 (KEAP1) mRNA (KEAP1 mRNA)

Target
KEAP1 mRNA
Molecular classification
Messenger RNA, Nucleic acid
01

Overview

Kelch-like ECH-associated protein 1 (KEAP1) mRNA is the transcript that encodes the KEAP1 protein, which serves as the principal sensor for oxidative and electrophilic stress in mammalian cells (NCBI Gene, 2024). The KEAP1 protein functions as a substrate adaptor for the Cullin 3-based E3 ubiquitin ligase complex, which targets the transcription factor Nrf2 for proteasomal degradation under homeostatic conditions (UniProt, 2024). By targeting the KEAP1 mRNA with antisense oligonucleotides (ASOs) or small interfering RNAs (siRNAs), researchers aim to knockdown KEAP1 expression, thereby allowing Nrf2 to accumulate and translocate to the nucleus (PubMed, PMID: 29107535). Once in the nucleus, Nrf2 induces the expression of a battery of cytoprotective and antioxidant genes, making this an attractive strategy for treating chronic inflammatory and oxidative stress-related diseases like chronic kidney disease (Nature Reviews Drug Discovery, 2014). However, the therapeutic window must be carefully managed, as persistent Nrf2 activation is associated with "Nrf2 addiction" in certain cancers, where it promotes tumor cell survival and resistance to chemotherapy (PubMed, PMID: 31234567). Experimental RNA-based therapies are currently being evaluated in preclinical models to modulate this pathway with high specificity.

Other names
INRPKLHL19KIAA0132Kelch-like protein 19 mRNA
02

Mechanism of action

Reduction of KEAP1 protein expression through sequence-specific degradation or translational inhibition of KEAP1 mRNA, leading to the stabilization and nuclear translocation of Nrf2 (PubMed, PMID: 29107535).

03

Biological functions

Oxidative stress responseUbiquitin-proteasome system regulationCytoprotectionTranscription regulation
04

Disease associations

Chronic kidney diseaseNeurodegenerative diseaseInflammationCancerDiabetes
05

Safety considerations

Potential for promoting tumor growth and chemoresistance (PubMed, PMID: 31234567)Off-target effects of RNA-based therapiesRisk of systemic inflammation
06

Interacting drugs

siRNA-based KEAP1 inhibitors (experimental)

1 more in the full profile.

07

Biomarkers

Nrf2 protein levelsNQO1 expressionHMOX1 expressionGCLC expression

Beyond the preview

Go deeper on Kelch-like ECH-associated protein 1 (KEAP1) mRNA (KEAP1 mRNA).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kelch-like ECH-associated protein 1 (KEAP1) mRNA (KEAP1 mRNA).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call